Annovis achieves comprehensive intellectual property (IP) protection now covering both the original semi-crystalline and new ...

Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.84 per share payable October 31, 2025, to shareholders of record at the close of business on September ...

(GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today announced ...

UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results ZUSDURI™ (mitomycin) for intravesical solution now available as the first and only ...

The podcast draws on insights from recent industry data, regulatory updates, and the Company’s own developments, offering a fresh perspective on Izotropic’s mission and its flagship product, IzoView, ...

Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a peer-reviewed publication from a team led by Manon Delafoy from the Institut Necker Enfants Malades (INEM) and colleagues from multiple French ...

Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, filed a patent infringement lawsuit against Balt ...

About VIVO ™ Catheter Precision’s VIVO (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, ...

Nualtis (formerly IntelGenx Corp.), a leader in oral film drug delivery technologies, today announced a strategic partnership with OrthoNu LLC to develop and manufacture an innovative portfolio of ...

Financial Results for the Second Quarter and Six Months Ended June 30, 2025 Please note: All share amounts and per share amounts in this press release have been adjusted to reflect the 1-for-8 reverse ...

WOBURN, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today ...

Belite Bio, Inc is a clinical stage drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases with significant unmet medical needs, such as Stargardt ...